Within the last decade, the WHO grading system of gliomas that is historically based upon histopathologic markers of malignancy has been significantly altered and augmented by use of molecular alterations like isocitrate dehydrogenase (IDH)-1/2-mutation [5]. The gene discussed is IDH1; the disease is glioma.